ClinicalTrials.gg
RecruitingNCT04735835Updated Apr 16, 2025

Personalized Responses to Dietary Composition Trial 3

An interventional study of Dietary Intervention in Diabetes, Heart Diseases and Diet Habit, sponsored by Zoe Global Limited. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-16.

Sponsored by Zoe Global Limited · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2020, registered Jan 2021).
  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,023 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Planned enrollment
Largest of 2,502
250,000 · median 82
Started
2020
with 94 others
No phase
1,418 of 3,023
159 open now
Primary completion
2030-01
later than 341 of 380 live
Registered
2,461st of 3,023
by date

Among the 3,023 studies in Diabetes Mellitus with a site in United States, this one has the largest planned enrollment of the 2,502 interventional ones that give a count, is one of 95 that started in 2020, is one of 1,418 with no phase, reaches primary completion later than 341 of the 380 other live ones, and was the 2,461st registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,023 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,023 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

The PREDICT 3 study will build on previous research in over 2,000 individuals to further refine machine learning models that predict individual responses to foods, with the aim of advancing precision nutrition science and individualized dietary advice. The study incorporates both standardized and controlled dietary intervention, for the purpose of testing postprandial responses to specific mixed meals, in addition to a free-living period with a dietary record for measuring responses to a large variety of meals consumed in a realistic context, where the role of external factors (e.g. exercise, sleep, time of day) on postprandial responses may be determined. For the first time this PREDICT study is built on top of a commercial product which will allow access to a much larger group of participants who are already collecting large amounts of data through digital and biochemical devices that can contribute to science.

Read the detailed description

Choice of design: The study is a single arm mechanistic intervention study.

Study population: The subject must have enrolled in the commercial ZOE testing program in order to apply for participation in the PREDICT 3 research program.

Screening Assessment: The study eligibility criteria listed below closely match to the commercial eligibility criteria, which ZOE users consent to before enrolling in the commercial program.

Study duration: Each participant will take part in the study for 6-14 days.

Dietary intervention: The dietary intervention will be carried out on up to 6 days with the option to continue monitoring for a total study period of 14-days. On day one, participants will be asked to fit glucose monitor. Over the following consecutive days, each participant will be instructed to eat 2 standardized meals. Participants are free to eat whatever they wish at all other times. The standardized meals will be provided to all participants by the study team via post. The foods included as part of these meals will be foods that are commonly consumed and can be made from products sold in US supermarkets. Participants will be asked to consume the entire amount of food indicated for the standardized meals and to record any left-over food via a digital app for which training will be provided at the start of the study. Following completion of standardized meal period, participants are free to eat and drink whatever they wish and will be asked to track all meals, snacks and drinks on their digital app. Participants will also be advised not to change their physical activity patterns during the course of the study.

Regular contact will be made with the participants via phone, their app and text messages for the period of the intervention to encourage compliance and answer any queries.

Anthropometry: The participant will be instructed to report height and weight.

Dietary and Lifestyle: Participants will be asked to complete a baseline questionnaire online, as well as a diet history questionnaire with portion sizes about the month preceding their study period. They will be asked to record on a daily basis their dietary, activity, and psychological data (e.g. hunger) using a digital mobile phone app. Training in all apps and equipment will be given through written and online instructions and via communications with the study support staff.

Digital devices: Participants will be asked to record daily dietary and activity information using digital apps and lifestyle information will be monitored using a wearable device. The continuous glucose monitor (Freestyle Libre, CGM) provides continuous glucose profiles for up to 14 days. The CGM will be inserted on the back of the upper arm, one day before participants begin dietary intervention. This will measure subcutaneous interstitial fluid glucose concentrations every 5 minutes. The CGM will be removed at the end of the intervention period by the participant. A contact number will be made available to participants for any inquiries or if any problems arise. Data from the CGM will be downloaded, and glucose profiles will be evaluated on the basis of data collected.

Meal responses: As a product user, the participant will consume standardized meals an additional day to the study intervention.

Blood samples: As a product user, the participant will collect postprandial blood on 1 day using finger-prick blood sampling.

Stool sample: As a product user, the participant will collect a stool sample on 1 day.

Digital app: As product users, participants will be asked to download an app designed specifically for this study, which provides diet logging functionality similar to widely used existing apps such as MyFitnessPal.

Participants will be asked to record and monitor the following information via the digital app:

  • All food and drink they consume, with serving sizes and photos
  • Sleep and physical activity patterns, including exercise
  • Hunger and alertness ratings
  • Psychological feeling of energy and mood
  • Prescription and over-the-counter drug consumption

The app will be available in versions for iOS operating systems. The app will synchronize remotely with backend database servers, over an encrypted and authenticated API, and will support offline operation for when patients wish to record an entry without network coverage. This continuous background synchronization means that it will not be necessary to explicitly download data from the phone at the end of the study.

Following the 2020 pandemic of COVID-19, participants are asked to use the COVID-19 Symptom Tracker app to record their physical health symptoms, or lack thereof, attributable to COVID-19, as well as demographic and other health information to track the spread of disease in real time, and to potentially reveal risk factors for infection and severe illness.

Subcohort: An opt-in follow-on study will be offered to participants to follow dietary guidance from the ZOE app based on their PREDICT 3 results. During the first 4 weeks, participants will be given dietary guidance to follow from the ZOE app. Thereafter, for a period of up to 12 months, participants will be asked to report on outcome measures at regular intervals (monthly). Outcome measures will be reported before, during and after the 4 week period and include weight, bristol stool chart, bowel habits, hunger, energy, adherence to dietary advice, and app usage. Participants (UK only) will collect additional stool samples at variable intervals.

The data will be used to test the efficacy of the ZOE dietary advice in promoting weight loss and improvement of overall health, and may be stratified by age, sex, BMI, adherence and/or motivation to take part in the PREDICT 3 study.

Food Frequency Questionnaire Validation: A food-frequency questionnaire (FFQ) developed using the most frequently logged foods within the ZOE app will be validated against a 4-day period of food logging in the app as well as the commonly used US-based DHQ3 FFQ (target enrollment; n=100).

03

Conditions studied

  • Diabetes
  • Heart Diseases
  • Diet Habit
  • Diet Modification
  • Healthy
  • Obesity
  • Metabolism
  • Microbial Colonization

Keywords

  • Gut microbiome
  • Personalised nutrition
  • Machine learning
  • Postprandial metabolism
  • Metabolic health
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Enrolled in the commercial ZOE testing program
  • Any sex
  • Minimum 18 years of age (minimum 19 years of age in Alabama and Nebraska due to state laws)
  • (BMI) of greater than or equal to 16.5 kg/m2.
  • Living in the continental US states, other than in New York (excluded from the ZOE testing product also as they are unable to access the dried blood spot service provided by Quest), or living in the UK
  • Able and willing to comply with the study protocol and provide .
  • Under care for chronic medical conditions (including eating disorders, type 1 diabetes, type 2 diabetes), and confirm they have checked with their primary care physician that this study is safe for them (US cohort only)

Exclusion criteria

Exclusion Criteria:

  • Cannot safely eat the pre-made test meals which contain standard US ingredients, e.g. due to allergy or recent gastrointestinal surgery, or are unwilling to consume these foods.
  • Are pregnant.
  • Have had a heart attack (myocardial infarction), stroke/ (TIA), or major surgery in the last two months.
  • Are unable to read and write in English, as the ZOE app is only available in English.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250,000 participants (estimated)

Study arms

  • Experimental
    Dietary Intervention

    Dietary intervention using standardized test meals after which the postprandial metabolic response is measured.

    Other: Dietary Intervention

Interventions

  • OtherDietary Intervention

    To carry out a dietary intervention using standardized test meals, where the participant's postprandial response to the meal is measured and is used to predict their postprandial responses to other foods, along with input variables including metabolic profile, anthropometry, sleep and exercise.

06

What researchers measure

Primary outcomes

  1. Glucose

    Measurement of blood glucose by continuous glucose monitor (mmol/L)

    Time frame: 6-14 days

  2. Gut microbiome species richness

    Species count in fecal sample (as part of ZOE testing program)

    Time frame: 1 day

  3. Blood Lipids

    Measurement of baseline and 6-h post-prandial triglycerides (mmol/L) by dried blood sample (as part of ZOE testing program)

    Time frame: 1 day

  4. Hunger and appetite assessment

    Self-reported in-app question on energy levels (categorical) (as part of ZOE testing program)

    Time frame: 6-14 days

  5. Glucose and HbA1c

    Measurement of baseline glucose (mmol/L) and HbA1c (%) by dried blood sample (as part of ZOE testing program)

    Time frame: 2 days

Secondary outcomes

  1. Dietary assessment

    Weighed food log

    Time frame: 6-14 days

  2. Anthropometry

    Weight (kg) (as part of ZOE testing program)

    Time frame: 1 day

  3. Anthropometry

    Height (cm) (as part of ZOE testing program)

    Time frame: 1 day

  4. Dietary assessment

    Diet history and portion size questionnaire about the preceding month (as part of ZOE testing program)

    Time frame: 1 month

  5. Bowel Type and Habit

    Measurement by Bristol Stool Chart and Questionnaire (as part of ZOE testing program)

    Time frame: 6-14 days

  6. Perceived Energy Assessment

    Self-reported in-app question on energy levels (categorical) (as part of ZOE testing program)

    Time frame: 6-14 days

  7. Covid-19 symptom assessment

    Self-reported demographic and physical health symptoms, or lack thereof, reported on a daily basis (as part of ZOE testing program)

    Time frame: 6 months

Other outcomes

  1. Adherence (in sub-cohort)

    Self-reported in-app question on daily frequency of adherence (categorical)

    Time frame: Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks)

  2. Hunger (in sub-cohort)

    Self-reported in-app question on hunger levels (categorical)

    Time frame: Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)

  3. Weight (in sub-cohort)

    Body Weight (kg)

    Time frame: Time Frame: 12 months: Baseline, Weekly (0 to 4 weeks), monthly (5 to 52 weeks)

  4. Bristol Stool Category (in sub-cohort)

    Self-reported in-app Bristol Stool chart question (categorical)

    Time frame: Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)

  5. Bowel Frequency (in sub-cohort)

    Self-reported in-app question on bowel frequency

    Time frame: Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)

  6. Energy (in sub-cohort)

    Self-reported in-app question on energy levels (categorical)

    Time frame: Time Frame: 12 months: Baseline, Daily (0 to 4 weeks), monthly (5 to 52 weeks)

  7. Waist Circumference (in sub-cohort)

    Self-reported in-app question on waist circumference

    Time frame: Time Frame: 12 months: Baseline, monthly (4 to 52 weeks)

  8. Hip Circumference (in sub-cohort)

    Self-reported in-app question on hip circumference

    Time frame: Time Frame: 12 months: Baseline, monthly (4 to 52 weeks)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Jan 2030, 113 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 113 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Feb 3, 2021
StartActual
Jul 20, 2020
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2030
Last update
Apr 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04735835
Lead sponsor
Zoe Global Limited
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
Jul 20, 2020
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Apr 16, 2025

Study contacts

Meaghan Reardon
Contact
meaghan@joinzoe.com
866-771-7478
Dan Sleeper
Contact
dan@joinzoe.com
866-771-7478
Tim Spector, PhD
principal investigator · Zoe Global Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion